2,201 material Form 8-K filings that 1,774 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Bio Green Med Solution reported second quarter 2026 results on August 12, 2026, with $336,000 in fire safety product revenue and a net loss of $0.4 million, compared with a $1.3 million net loss a year earlier. The company also disclosed a June 2026 Business Combination Agreement under which Future NRG Sdn. Bhd. shareholders would receive more than 99% of the combined company, which would matter to shareholders if the exchange closes.
Revenue of $336,000 for the quarter ended June 30, 2026, versus no revenue in the prior-year period, following the September 2025 acquisition of Fitters Sdn. Bhd.
Net loss of $0.4 million, or $(0.08) per share from continuing operations, compared with $1.3 million, or $(0.93) per share, a year earlier.
June 2026 Business Combination Agreement with Future NRG Sdn. Bhd.; the Exchange can be terminated by either party if not closed by December 31, 2026.
Cash and cash equivalents of $3.8 million as of June 30, 2026; the company estimates current resources will fund planned expenditure into the first quarter of 2027.
Dominari Holdings entered inducement agreements on August 13, 2026, with holders of Series A warrants covering up to 3,124,690 shares, offering a reduced $2.20 cash exercise price or a 5:1 share exchange. The company expects about $2.9 million in gross proceeds from cash exercises and about 115,000 new shares from exchanges, and about 1.2 million Series A warrants would remain outstanding, which the company says reduces market overhang.
Existing Series A warrants, issued February 14, 2025, had an original exercise price of $3.72 per share.
Option A: cash exercise at $2.20 per share on or before 4 p.m. ET on September 11, 2026.
Option B: exchange at 5:1, with one new share issued for every five underlying shares, for no additional consideration.
Company expects about $2.9 million in gross proceeds and about 115,000 shares issued under the options.
Creative Media & Community Trust Corporation (CMCT) reported a second-quarter 2026 net loss attributable to common stockholders of $11.0 million, or $4.03 per diluted share, compared with $14.3 million a year earlier. Total revenues were $29.7 million, roughly flat year over year, while total segment net operating income fell 5.2% to $9.3 million. The company also said it elected not to invest the capital needed to refinance the Oakland Office Building mortgage, which had an outstanding balance of $97.1 million and matured in the third quarter of 2026.
Net loss attributable to common stockholders was $11.0 million for the quarter ended June 30, 2026, versus $14.3 million in the same period of 2025.
FFO was $(3.5) million and Core FFO was $(3.4) million, compared with $(7.9) million and $(7.0) million a year earlier.
Total segment NOI decreased 5.2% to $9.3 million, while NOI excluding loss from unconsolidated entities rose 22.2% to $12.5 million.
The $97.1 million non-recourse mortgage on the Oakland Office Building matured in the third quarter of 2026; the company continues to engage with the servicer on a long-term resolution.
BK Technologies Corporation announced its financial and operating results for the quarter ended June 30, 2026, on August 13, 2026, through an amended press release and an earnings presentation. The filing does not state revenue, profit, or guidance figures, so the results' direction cannot be judged from this document alone.
Results cover the second quarter ended June 30, 2026, announced August 13, 2026.
The amended press release is furnished as Exhibit 99.1.
The earnings presentation is furnished as Exhibit 99.2 and is posted at www.bktechnologies.com.
The filing is signed by CFO Scott A. Malmanger, dated August 13, 2026.
Idaho Strategic Resources reported second-quarter 2026 revenue of $10,732,335, up 13.25% from a year earlier, with net income attributable to the company up 31.95% to $3,651,596. The company said a wildfire halted milling at its New Jersey mill for about a week in June and that a change in mining method and grade variations affected the quarter, and all-in sustaining cost per ounce rose 16.08% to $2,261.81.
Revenue was $10,732,335 for Q2 2026, up 13.25% from $9,476,739 in Q2 2025.
Net income attributable to IDR was $3,651,596, up 31.95%; EPS was $0.23 versus $0.20.
Average flotation feed grade fell 20.86% to 7.89 gpt; ounces produced rose 1.23% to 3,047.
All-in sustaining cost per ounce rose 16.08% to $2,261.81; average realized gold price was $4,277.53, up 32.70%.
Circle8 Group said on August 10, 2026 that it signed a settlement with SPP Credit Advisors that resolves pending New York and Delaware litigation and cancels its $35 million convertible seller's note. The company will issue 21,983,926 shares to SPP, while it gains an option to buy and retire the same number of shares for $0.00001 each, and SPP's remaining debt is to be repaid over an 18-month share disposition period. Separately, Nasdaq notified the company on August 13, 2026 that its stock has closed below $1.00 for 30 consecutive business days.
The $35,000,000 convertible promissory note is released, canceled and discharged; SPP indebtedness was $62,669,730.00 as of August 7, 2026, bearing 5% interest during the disposition period.
Atlantic agrees to issue 21,983,926 shares to SPP, with a ten-year call option to buy the same number of shares at $0.00001 per share for retirement.
Lyneer Staffing agreed to seek refinancing of its SLR facility within 45 days of August 7, 2026, with a $5 million payment to SPP upon refinancing.
Nasdaq's August 13, 2026 letter cites a $1.00 minimum bid price; the filing lists February 9, 2026 as the regain-compliance date and says the stock will continue to trade as CIRC.
Interlink Electronics reported results for the quarter ended June 30, 2026. Revenue rose 10% to $3.77 million, and net income was $248,000, compared with $100,000 a year earlier. The company also said it is exploring debt financing for a pending acquisition it expects to complete by the end of October 2026.
Q2 2026 revenue was $3.77 million, up 10.4% from $3.41 million in Q2 2025
Q2 2026 net income was $248,000 versus $100,000 a year earlier; first-half net loss narrowed to $90,000 from $705,000
Q2 2026 gross margin was 44.4%, down from 45.0%; first-half gross margin rose to 44.0% from 40.9%
Acquisition announced in May 2026 is expected to close by the end of October 2026; company is exploring debt financing options
REalloys reported second-quarter 2026 net revenues of $0.8 million, up from $0.4 million a year earlier, but its net loss widened to $36.8 million, or $0.59 per diluted share, from $2.2 million, or $0.05 per share. The company said the increase was driven mainly by $32.1 million of non-cash stock-based compensation, and it ended the quarter with $122.4 million in cash, which it says covers its committed strategic project funding without additional financing.
Net revenues were $0.8 million for the quarter ended June 30, 2026, compared with $0.4 million a year earlier.
Net loss was $36.8 million, or $0.59 per diluted share, versus $2.2 million, or $0.05 per share, in the prior-year quarter.
Non-cash stock-based compensation of $32.1 million was the main driver of the higher loss.
Cash was $122.4 million at June 30, 2026, after a $100.0 million private placement closed in June 2026; Craig Cunningham became Chief Financial Officer effective June 24, 2026.
Dawson Geophysical reported unaudited second-quarter 2026 revenue of $17.9 million, up 82% from a year earlier, but a net loss of $3.4 million, or $0.11 per share, which was wider than the $2.3 million loss in the second quarter of 2025. The loss included $1.7 million of strategic transaction costs tied to discussions with controlling stockholder Wilks Brothers, LLC, which the filing says controls about 80% of the common stock. There is no guarantee a definitive agreement will be reached, and a special committee of independent directors is evaluating any such transaction.
Second-quarter fee revenue was $14.0 million, up 60%; total revenue was $17.9 million, up 82% from $9.9 million.
Second-quarter net loss was $3.4 million, or $0.11 per share, including $1.7 million of strategic transaction costs; Adjusted EBITDA was $0.6 million versus negative $1.2 million a year earlier.
Six-month net income was $4.2 million, or $0.14 per share, including $2.4 million of strategic transaction costs.
Discussions with Wilks Brothers, LLC and its affiliates on possible transactions are ongoing; no definitive agreement has been reached.
Lument Finance Trust reported a GAAP net loss attributable to common shareholders of $9.2 million, or $0.18 per share, for the quarter ended June 30, 2026, and a Distributable Loss of $5.3 million, or $0.10 per share. The board also approved a 1-for-10 reverse stock split, which the company says is intended to regain compliance with New York Stock Exchange listing requirements; for shareholders, the number of shares falls from about 52.5 million to about 5.3 million while ownership percentages are unchanged apart from cash paid for fractional shares.
Q2 2026 GAAP net loss attributable to common shareholders of $9.2 million, or $0.18 per share
Q2 2026 Distributable Loss of $5.3 million, or $0.10 per share, versus Distributable Earnings of $0.02 per share in Q1 2026
Reverse split expected to take effect at 5:00 pm ET on September 9, 2026, with split-adjusted trading beginning September 10, 2026 under ticker LFT
Book value per share of common stock was $2.76 as of June 30, 2026, down from $2.97 in the prior quarter; a $0.04 per share common dividend was declared
Marqeta said its Chief Accounting Officer and principal accounting officer, Sarah Barkema, will resign effective August 21, 2026, and that her departure is not due to any disagreement over financial statements, internal controls, operations, policies or practices. CFO Patti Kangwankij will take over the principal accounting officer role, and the company plans to search for a new Chief Accounting Officer.
Sarah Barkema informed the company of her resignation on August 10, 2026; effective date is August 21, 2026
The company states the departure involves no disagreement on financial statements, internal control, operations, policies or practices
CFO Patti Kangwankij will become principal accounting officer after Barkema leaves
The company intends to search for a new Chief Accounting Officer; no successor is named
Cloudflare issued $2.5 billion of 0% convertible senior notes maturing August 15, 2031, under an indenture dated August 13, 2026. The company reported net proceeds of about $2,462.3 million, of which $259.5 million was used for capped call transactions, with the remainder for general corporate purposes. The notes add a large amount of debt, and conversion into Class A common stock would dilute shareholders unless offset by the capped calls.
Principal of $2.5 billion, 0% interest, maturing August 15, 2031 unless earlier redeemed, repurchased or converted.
Initial conversion price of about $496.94 per share, a 60% premium to the $310.59 closing price on August 10, 2026.
Net proceeds of about $2,462.3 million; $259.5 million used to pay for capped call transactions.
No optional redemption before August 20, 2029, except a cleanup redemption if less than $200.0 million remains outstanding.
Nuwellis reported second-quarter 2026 net sales of $2.0 million, up 14% from the prior-year quarter, and gross margin of 76% versus 56% a year earlier. The net loss narrowed to $4.8 million from $12.6 million, though it included about $1.7 million of non-cash warrant valuation expense. The company said about $12.7 million in gross proceeds from June and July financings and warrant exercises extends its cash runway through the second quarter of 2027.
Q2 net sales $2.0 million, up 14%; U.S. revenue up 17%
Q2 gross margin 76%, compared with 56% in the prior-year quarter
Q2 net loss $4.8 million, versus $12.6 million; includes about $1.7 million non-cash warrant expense
Cash of $3.9 million at June 30, 2026; about $12.7 million gross raised in June and after quarter-end
AbCellera priced an underwritten public offering of 17,435,897 common shares at $9.75 per share, plus pre-funded warrants for up to 3,076,926 shares, with closing expected on or about August 14, 2026. The company estimates net proceeds of about $187.0 million and plans to use them to fund its internal pipeline, including lead clinical program ABCL635, and for working capital. The new shares will add to the existing share count, which dilutes current shareholders' ownership.
Priced 17,435,897 common shares at $9.75 per share, and pre-funded warrants for up to 3,076,926 shares at $9.74999 each
Gross proceeds expected to be about $200.0 million; estimated net proceeds about $187.0 million after underwriting discounts, commissions and offering expenses
Proceeds to fund research, development and clinical advancement of the internal pipeline, including ABCL635, and for working capital and general corporate purposes
Closing expected on or about August 14, 2026; the company and its executive officers and directors agreed to a 60-day restriction on share sales, subject to exceptions
BNY's board elected Vikram Malhotra, a senior partner at McKinsey & Company, as an independent director, effective October 1, 2026. With his addition, the board will have 12 directors, 11 of whom are independent. The filing describes a board seat with customary non-management director compensation and does not report any change to executive officers.
Board elected Malhotra on August 11, 2026, effective October 1, 2026
Board will consist of 12 directors, 11 of them independent
Malhotra has been a senior partner at McKinsey since 1998 and joined the firm in 1986
He will receive non-management director compensation as described in the March 5, 2026 proxy statement
Newmont and Barrick signed a Second Amended and Restated LLC Agreement for the Nevada Gold Mines joint venture, dated August 10, 2026, along with a confidential settlement that resolves all outstanding disputes related to the joint venture. Barrick's Fourmile project and Newmont's Fiberline and Mike projects will be contributed to Nevada JV, and Newmont will pay Barrick $1.95 billion in cash, a large cash outlay for the company. The filing does not state how the transaction affects Newmont's earnings or financial results.
Newmont Member will pay Barrick Member $1.95 billion in cash within 30 days after the Fourmile project is contributed to Nevada JV.
Newmont is deemed to have made a $1.95 billion capital contribution and Barrick is deemed to have made an approximately $3.11 billion capital contribution to Nevada JV.
The settlement resolves all outstanding disputes related to Nevada JV, and Newmont has provided its consent to Barrick's proposed North American IPO.
Upon completion of the contribution of the Projects, Nevada JV will assume all liabilities associated with those Projects.
CPI Aerostructures reported results for the quarter ended June 30, 2026, with revenue of $17.6 million, up from $15.2 million a year earlier, and net income of $0.7 million, or $0.05 per diluted share, compared with a net loss of $1.3 million in the same quarter of 2025. For the six months, revenue was $34.9 million and net income was $1.9 million, compared with a net loss of $2.6 million a year earlier, and the company cited a total backlog of $533 million.
Q2 2026 revenue of $17.6 million vs. $15.2 million in Q2 2025; gross margin of 22.0% vs. 4.4%
Q2 2026 net income of $0.7 million ($0.05 per diluted share) vs. net loss of $1.3 million ($0.10 loss per share)
Six months 2026 net income of $1.9 million vs. net loss of $2.6 million; adjusted EBITDA of $3.5 million vs. $(2.5) million
Total backlog of $533 million, including $433 million unfunded backlog of future orders
Xylem expanded its Board of Directors from 9 to 10 members and appointed D. Christian Koch to fill the new seat, effective immediately on August 13, 2026. The Board determined Koch is independent, and he also joined the Leadership Development and Compensation Committee and the Nominating and Governance Committee. Koch currently serves as Chairman, President and Chief Executive Officer of Carlisle Companies Incorporated, and the filing states he will receive standard non-employee director compensation, prorated for the current term.
Board size increased from 9 to 10 directors; Koch appointed to fill the vacancy effective August 13, 2026
Koch joins the Leadership Development and Compensation Committee and the Nominating and Governance Committee
Board determined Koch is independent under NYSE listing standards and SEC rules
Koch is Chairman, President and CEO of Carlisle Companies Incorporated; compensation follows the 2026 Proxy Statement filed March 20, 2026, prorated for the current term
CAMP4 Therapeutics reported a second-quarter 2026 net loss of $33.5 million, up from $12.6 million a year earlier, mainly due to a $20.9 million non-cash loss from a change in fair value of a derivative tranche liability tied to its September 2025 private placement. Revenue rose to $1.8 million from $1.5 million, and the company said its cash is sufficient to fund planned activities through the end of 2028.
Net loss for the quarter ended June 30, 2026, was $33.5 million, compared with $12.6 million a year earlier.
Research and collaboration revenue was $1.8 million, up from $1.5 million; R&D expenses were $10.8 million and G&A expenses were $4.3 million.
Cash and cash equivalents were $86.4 million at June 30, 2026, down from $109.5 million at December 31, 2025; the company closed a second private placement tranche raising $50.1 million after quarter-end.
Regulatory clearance was received in Australia and Argentina for a Phase 1/2 trial of CMP-002, with trial launch expected in Q4 2026.
Oxbridge Re Holdings reported net income of $176,000, or $0.02 per share, for the quarter ended June 30, 2026, compared with a net loss of $1.87 million a year earlier. The company recorded no underwriting losses in the quarter, and total revenue rose to $940,000 from $664,000, helped by $501,000 of SurancePlus management fee income. The filing also announced AI GridWorks, a new subsidiary to develop, own and operate AI data centers.
Q2 2026 net income was $176,000, or $0.02 per share, versus a net loss of $1.87 million, or $0.25 per share, in Q2 2025.
Net premiums earned fell to $368,000 from $582,000, while no underwriting losses were recorded in Q2 2026 compared with a full limit loss on one reinsurance contract in Q2 2025.
Restricted cash and cash equivalents rose $12.85 million to $19.82 million as of June 30, 2026, from $6.98 million at December 31, 2025.
AI GridWorks was launched after quarter-end to develop, own and operate AI data centers; the filing does not state its funding or capital commitment.
On August 13, 2026, Illumina entered into a new $1,000 million senior unsecured five-year revolving credit facility with Bank of America, N.A. as administrative agent, which replaces the Existing Credit Agreement dated January 4, 2023, that was terminated the same day. As of the filing date, no borrowings were outstanding, and the facility matures on August 13, 2031, subject to extension options.
Facility size: $1,000 million senior unsecured five-year revolving credit, with a $50 million swingline sublimit and a $75 million letter of credit sublimit
Option to add up to $500 million in term loans or commitment increases, subject to lender consent
No borrowings outstanding as of the filing date; maturity August 13, 2031
Existing Credit Agreement dated January 4, 2023 was terminated as of August 13, 2026
Veritone reported second-quarter 2026 revenue of $24.3 million, up 4.6% from a year earlier, while its operating loss widened 16.4% to $22.1 million, including $4.5 million in restructuring expenses. Net loss narrowed to $22.2 million, mainly due to lower interest expense, and the company is targeting $3.5 million to $8.5 million in additional cost reductions by year-end 2026. For shareholders, revenue and full-year guidance point up, but gross margin fell and the operating loss grew.
Q2 2026 revenue was $24.3 million, up $1.1 million from Q2 2025; Annual Recurring Revenue was $62.0 million, up 0.2%.
Operating loss was $22.1 million versus $19.0 million a year earlier; net loss was $22.2 million versus $26.5 million, helped by $3.2 million lower interest expense.
GAAP gross margin fell to 58.5% from 67.5%, and total Software Products & Services customers declined 7.7% to 2,829.
Full-year 2026 outlook: revenue of $100 million to $115 million versus $92.6 million in fiscal 2025; non-GAAP net loss of $22.0 million to $32.0 million versus $40.8 million.
Life Time, Inc. and certain subsidiaries entered into a Sixteenth Amendment to their credit agreement on August 12, 2026, refinancing the $985 million 2026 Term Loan Facility. The interest rate margin falls 0.25 percentage points to 1.75%, and with interest rate swaps the effective fixed rate is now 5.159%. The loan still matures on November 5, 2031, so the change lowers borrowing costs without extending the debt's term.
Amendment dated August 12, 2026 covers the $985 million 2026 Term Loan Facility
Interest rate margin reduced by 0.25% to 1.75%
Effective fixed interest rate, including swaps, is now 5.159%
Loans were issued at par with no original issue discount; maturity remains November 5, 2031
KULR Technology Group reported second quarter 2026 results that worsened on the headline measures: revenue fell 43% year over year and the company posted a net loss of $21,970,816, compared with net income a year earlier. The company attributed the loss mainly to a $10,591,667 fair value loss on its bitcoin holdings and said it has since exited Bitcoin mining and repaid its Coinbase loan in full.
Revenue decreased 43% to $2,080,177 in the quarter ended June 30, 2026, from $3,652,471 a year earlier.
Net loss was $21,970,816, or $0.47 per share, versus net income of $8,142,149, or $0.22 per share, a year earlier.
Loss from operations rose 19% to $11,204,578; gross margin was (31)% versus 20% a year earlier.
Cash balance was $12.8 million as of June 30, 2026; the company says it did not issue any shares through its ATM in the first half of 2026.
NextPlat reported second-quarter 2026 revenue of $11.9 million, down from $13.2 million a year earlier but up 21% from the first quarter. The net loss narrowed to $144,000, or $0.05 per diluted share, from $1.8 million, or $0.69 per share, in the prior-year quarter. The company's gross margin of about 40% was a record, but the filing gives no revenue or earnings guidance figures.
Revenue was $11.9 million, down from $13.2 million a year earlier and up about 21% from $9.9 million in the first quarter of 2026.
Gross margin was about 40%, a record, compared with 22% in the second quarter of 2025.
Net loss attributable to common stockholders was $144,000, or $0.05 per diluted share, versus $1.8 million, or $0.69 per share, a year earlier; the company cites about $0.5 million in one-time professional fees.
Cash was $11.9 million at June 30, 2026, with no material unsecured debt; the company also announced an intended acquisition of a pharmacy operation in the Pensacola area.
Addus HomeCare said President and Chief Operating Officer Heather Dixon left the company on August 7, 2026. The company appointed W. Bradley Bickham, its former president and COO, as interim COO on the same day, under an employment agreement that runs through July 31, 2027.
Heather Dixon, President and Chief Operating Officer, left the company on August 7, 2026.
W. Bradley Bickham, age 63, was appointed interim Chief Operating Officer on August 7, 2026.
Bickham's employment agreement, dated August 10, 2026, sets an annualized base salary of $622,000 plus fixed bonuses.
Bickham previously served as President and COO from March 2021 to September 2025 and as Advisor to the CEO from September 2025.
QXO reported second-quarter 2026 results for the three months ended June 30, 2026. Net sales rose to $3,246 million from $1,906 million a year earlier, and the company said the increase includes $595 million attributable to the Kodiak business acquired April 1, 2026, but GAAP net loss was $55 million versus $59 million, while Adjusted Diluted EPS fell to $0.08 from $0.11.
Net sales were $3,246 million for the quarter, up from $1,906 million, including $595 million from Kodiak.
Basic and diluted loss per share was $(0.14), compared with $(0.15) a year earlier.
Adjusted EBITDA was $272 million, up from $204 million, and Adjusted Diluted EPS was $0.08, down from $0.11.
The TopBuild acquisition was completed on July 1, 2026, after the quarter ended.
AmpliTech Group reported unaudited second-quarter 2026 revenue of $8.07 million, up about 50.9% from $5.35 million in the first quarter, and gross profit of $2.25 million, up 161.2% year over year. The net loss widened to $3.09 million from $1.77 million a year earlier as research and development and selling, general and administrative spending increased. Shareholders also saw the July 22, 2026 close of the Series A Rights process, which brought approximately $20.12 million in net proceeds.
Q2 2026 revenue was $8.07 million, versus $5.35 million in Q1 2026.
Gross margin was 27.9%, compared with 48.0% in Q1 2026 and 7.8% in Q2 2025.
Net loss was $3.09 million, versus $1.77 million in Q2 2025; R&D expense was $1.37 million.
Series A Rights closed July 22, 2026, with approximately $21.92 million gross and $20.12 million net proceeds.
FS KKR Capital Corp. said it will post investor presentations on its website after the market close on August 13, 2026, under the Events & Presentations page. The filing contains no financial results, guidance, or new financial figures, so it offers shareholders no new measurable information beyond the posting itself.
Investor presentations to be posted on the company website after market close on August 13, 2026
Presentations are listed under the Events & Presentations page in the For Investors section
Filing is a Regulation FD disclosure; the company states it does not update the presentations except as securities laws require
Elutia reported second quarter 2026 results with net sales down to $2.4 million from $2.7 million, while its net loss narrowed to $7.6 million from $9.6 million. The company said it has secured up to $26 million in additional capital to fund NXT-41x through anticipated FDA clearance and its first full year of commercial launch, without an equity offering, which matters to shareholders because it reduces near-term dilution risk.
Q2 2026 net sales were $2.4 million versus $2.7 million a year earlier, due mainly to a $0.7 million reduction in SimpliDerm revenue from a contract manufacturer production disruption.
Adjusted EBITDA was a loss of $4.6 million versus a loss of $3.0 million in the prior-year quarter.
Up to $26 million of capital includes a $15 million credit facility ($10 million funded at closing) and up to $11 million from the SimpliDerm divestiture.
Cash and cash equivalents were $19.9 million at June 30, 2026, and the company expects the full $8 million BioEnvelope escrow to be released in the fourth quarter of 2026.
Fortress Biotech reported second quarter 2026 net revenue of $18.7 million, up 14% from $16.4 million a year earlier, and a net loss attributable to common stockholders of $2.5 million, or $0.08 per share, compared with net income of $13.4 million, or $0.50 per share basic, in the second quarter of 2025. Operating expenses fell sharply, with research and development at $0.8 million versus $8.1 million and selling, general and administrative costs at $20.8 million versus $38.8 million, and cash and cash equivalents rose to $196.6 million as of June 30, 2026 from $79.4 million at December 31, 2025.
Net revenue was $18.7 million for the quarter, of which $17.8 million came from marketed dermatology products, compared with $16.4 million a year earlier.
Loss from operations narrowed to $10.0 million from $36.5 million, driven mainly by lower SG&A and R&D expenses.
Net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, versus net income of $13.4 million, or $0.50 per share basic, in the prior-year quarter.
Partner Crystalys Therapeutics announced a $130 million Series B financing in July 2026 for dotinurad, on which subsidiary Urica is entitled to a 3% royalty on future net sales.
Cineverse reported results for the fiscal first quarter ended June 30, 2026. Revenue rose 175% to $30.6 million, mainly from the Giant Worldwide and IndiCue acquisitions, but the net loss attributable to common stockholders widened to $5.8 million, or $0.28 per share, from $3.6 million, or $0.21 per share, a year earlier. The company reaffirmed its full fiscal 2027 guidance of $115 to $120 million in revenue and $10 to $20 million in Adjusted EBITDA.
Revenue was $30.6 million versus $11.1 million in the prior-year quarter, a 175% increase.
Net loss attributable to common stockholders was $(5.8) million, or $(0.28) per share, versus $(3.6) million, or $(0.21) per share.
Adjusted EBITDA was $0.5 million, an increase of $2.6 million over the prior year.
Full fiscal 2027 guidance was reaffirmed at $115 to $120 million in revenues and $10 to $20 million in Adjusted EBITDA.
Cibus reported second-quarter 2026 results, with revenue of $994,000 versus $933,000 a year earlier and a net loss of $22.1 million versus $26.6 million. Loss per Class A share was $0.29 compared with $0.61, and the company said it expects cash to fund planned operations into early in the first quarter of 2027. Shareholders get a smaller loss and higher revenue, but cash of $20.4 million remains limited and the company may pursue financing.
Q2 2026 revenue was $994,000 versus $933,000 in Q2 2025; net loss was $22.1 million versus $26.6 million.
Net loss per Class A share was $0.29 versus $0.61 a year earlier, which the company attributed mainly to cost reduction initiatives and higher weighted average shares.
Cash and cash equivalents were $20.4 million as of June 30, 2026; the company expects this to fund operations into early Q1 2027 before any potential financing.
The company expects an annual net cash usage run-rate of about $35 million exiting 2026. Craig Wichner was appointed CEO effective June 8, 2026.
Sensus Healthcare reported second-quarter 2026 revenue of $2.3 million, down $5.0 million from the prior-year quarter, and a net loss of $8.7 million, or $0.53 per share. The company said a sale of eight units was not recorded in Q2 because of financing approval timing and will be recognized in Q3, while a $5.7 million tax expense that includes a valuation allowance against deferred tax assets added to the loss.
Q2 2026 revenue was $2.3 million versus $7.3 million in Q2 2025, with 11 units sold compared with 19 a year earlier.
Net loss was $8.7 million, or $0.53 per share, compared with a net loss of $1.0 million, or $0.06 per share, in Q2 2025.
Adjusted EBITDA, a non-GAAP measure, was negative $3.0 million versus negative $1.8 million a year earlier.
Cash, restricted cash and cash equivalents fell to $15.2 million at June 30, 2026, from $18.3 million at March 31, 2026.
WidePoint Corporation disclosed that Executive Vice President and Chief Revenue Officer Jason Holloway tendered his resignation on August 7, 2026, effective December 31, 2026. The company said the departure is for personal and family reasons and not due to any disagreement with the company.
Jason Holloway resigned as Executive Vice President and Chief Revenue Officer, tendered August 7, 2026.
Resignation is effective December 31, 2026.
Company states the departure is for personal and family reasons and involved no disagreement with the company.
The company thanked Mr. Holloway for his significant contributions.
Dillard's reported net income of $97.7 million, or $6.25 per share, for the 13 weeks ended August 1, 2026, up from $72.8 million, or $4.66 per share, a year earlier. The results include $37.2 million in IEEPA tariff refunds, and total retail sales rose 1%, so both sales and profit improved for shareholders.
Net income was $97.7 million, or $6.25 per share, versus $72.8 million, or $4.66 per share, in the prior-year second quarter.
Total retail sales rose 1% to $1.455 billion, and comparable store sales also rose 1%.
Net income includes $37.2 million in IEEPA tariff refunds ($1.82 per share after tax); the company does not expect additional significant refunds.
Retail gross margin was 40.9% of sales, compared with 38.1% a year earlier; operating expenses rose to $443.6 million from $434.2 million.
Trust Stamp reported results for the six months ended June 30, 2026, with net recognized revenue up 22% to $1.66 million. The net loss rose 27.29% to $4.93 million, and total operating expenses increased to $6.32 million, so higher revenue came with a larger loss for shareholders.
Net recognized revenue for the six months ended June 30, 2026 was $1.66 million, up 22% from $1.36 million, driven mainly by the S&P 500 bank customer and $192 thousand billed in Q2 for telecom work.
Net loss was $4.93 million versus $3.87 million a year earlier; basic and diluted loss per share was $0.90 compared with $1.57.
Total operating expenses were $6.32 million versus $5.20 million, including $1.42 million of non-cash expenses; cash and cash equivalents were $6.31 million at June 30, 2026.
Negotiations continue with a second African telecoms company and on three government-related contracts in Ghana, which the company expects to result in one or more definitive agreements during FY 2026.
Assembly Biosciences reported second quarter 2026 results, with collaboration revenue from Gilead rising to $13.4 million from $9.6 million and net loss falling to $3.9 million, or $0.20 per share, from $10.2 million, or $1.33 per share. The company completed $115 million in gross financing and said its cash position is projected to fund operations into 2029, which supports its pipeline programs.
Collaboration revenue was $13.4 million for the quarter ended June 30, 2026, compared with $9.6 million a year earlier, including a $5.1 million cumulative catch-up adjustment.
Net loss attributable to common stockholders was $3.9 million, or $0.20 per share, versus $10.2 million, or $1.33 per share, in the same period of 2025.
Cash, cash equivalents and marketable securities were $320.4 million at June 30, 2026, up from $226.6 million at March 31, 2026.
Completed $115 million gross financing; GS-1179 is expected to start a Phase 2 trial by year-end 2026.
Laird Superfood reported second quarter 2026 net sales of $41.3 million, up 244% from $12.0 million a year earlier, driven largely by the Navitas and Terrasoul acquisitions. The company's net loss widened to $1.8 million, or $0.25 per share, from $0.4 million, or $0.03 per share, mainly due to acquisition and integration costs; the company reaffirmed its full-year 2026 guidance.
Q2 net sales $41.3 million vs. $12.0 million in the prior-year quarter; gross margin 30.3% vs. 39.9%
Net loss $1.8 million, or $0.25 per share, vs. $0.4 million, or $0.03 per share; adjusted EBITDA $3.0 million vs. $0.1 million
Full-year 2026 guidance reaffirmed: net sales of $138 to $148 million and adjusted EBITDA of $8 to $12 million
Cash totaled $23.2 million at June 30, 2026, with no outstanding debt
Arcadia Biosciences reported second-quarter 2026 revenue of $1.4 million, down 1% from a year earlier, and a net loss attributable to common stockholders of $6.3 million, up from $4.5 million. The company attributed the revenue shortfall to low inventory and longer-than-expected shipping times, and the larger loss to non-operating items including a $5.4 million valuation loss on its June 2026 private placement and a $2.8 million unrealized loss on its Above Food stock.
Q2 2026 total revenues were $1.443 million versus $1.455 million in Q2 2025.
Q2 2026 net loss per share was $2.09, compared with $3.26 in Q2 2025.
The company raised $4 million in gross proceeds through a June 2026 private placement and reported $4.2 million in cash at June 30, 2026.
Intellicheck reported second-quarter 2026 revenue of $5.9 million, up 16% from a year earlier, and net income of $0.7 million, compared with a net loss of $0.3 million in the same quarter of 2025. The company also disclosed that a customer representing about 29% of first-half 2026 revenue is moving to a multi-source vendor setup and testing an alternative, which it expects to reduce transaction levels with that customer.
Q2 2026 revenue was $5.9 million, up 16% year over year and up 7% sequentially.
Net income was $0.7 million, or $0.03 per diluted share, versus a net loss of $0.3 million a year earlier; adjusted EBITDA was $1.1 million versus $0.1 million.
A customer that was about 29% of first-half 2026 revenue is shifting to a multi-source architecture; the main phase was scheduled to start in late July, and the company had not yet seen the planned volume reductions as of August 12, 2026.
The company had $11.8 million in cash and no debt at June 30, 2026.
Eledon Pharmaceuticals reported a second-quarter 2026 net loss of $31.6 million, or $0.27 per share, compared with $11.2 million, or $0.13 per share, a year earlier. The loss was driven largely by a $9.6 million non-cash charge from changes in warrant liabilities; excluding that item, the net loss was $22.0 million versus $23.5 million. Cash and short-term investments fell to $88.8 million, which the company expects to fund operations into the second quarter of 2027.
Q2 2026 net loss $31.6 million ($0.27 per share) vs. $11.2 million ($0.13 per share) in Q2 2025
Non-cash warrant liability loss of $9.6 million in Q2 2026 vs. a $12.3 million gain in Q2 2025
Excluding warrant items, net loss was $22.0 million vs. $23.5 million
Cash, cash equivalents and short-term investments were $88.8 million at June 30, 2026, funding operations into Q2 2027
Ames National Corporation declared a cash dividend of $0.24 per common share on August 12, 2026, as disclosed in an 8-K filed August 13, 2026. The dividend is payable September 15, 2026, to shareholders of record at the close of business on September 1, 2026, so holders on that record date will receive the payment.
Cash dividend of $0.24 per common share declared August 12, 2026
Record date: close of business September 1, 2026
Payment date: September 15, 2026
Company trades on the NASDAQ Capital Market under ticker ATLO
Caribou Biosciences reported a second-quarter 2026 net loss of $24.3 million, or $0.24 per share, compared with $54.1 million, or $0.58 per share, a year earlier. The prior-year figure included $21.3 million in non-cash impairment charges, and licensing and other third-party revenue fell to $1.5 million from $2.7 million. The company now expects its cash to fund its current operating plan to the end of 2027, but cash, cash equivalents, and marketable securities declined to $113.8 million as of June 30, 2026, and the company said it is exploring options to fully fund its planned ANTLER-3 trial.
Net loss of $24.3 million, or $0.24 per share, for the quarter ended June 30, 2026, versus $54.1 million, or $0.58 per share, a year earlier
Licensing and other third-party revenue of $1.5 million, down from $2.7 million in the same period of 2025
Cash, cash equivalents, and marketable securities of $113.8 million at June 30, 2026, down from $142.8 million at December 31, 2025
Cash now expected to fund the current operating plan to the end of 2027; the company is exploring multiple options to fully fund the ANTLER-3 trial
MacroGenics reported second-quarter 2026 revenue of $32.8 million, up from $6.9 million a year earlier, and net income of $19.5 million, compared with a net loss of $36.3 million. The profit reflects $89.2 million of income from discontinued operations tied to the sale of its manufacturing operations, while the loss from continuing operations widened to $69.6 million, including a $52.8 million non-cash loss on extinguishing a royalty monetization liability.
Q2 2026 total revenue was $32.8 million, versus $6.9 million in Q2 2025, driven mainly by a $24.5 million Sanofi regulatory milestone.
Net income was $19.5 million, or $0.31 per share, versus a net loss of $36.3 million, or $0.57 per share, a year earlier.
Loss from continuing operations was $69.6 million, compared with $42.7 million a year earlier, after a $52.8 million non-cash loss on extinguishment of the ZYNYZ royalty monetization liability.
Pro forma cash, cash equivalents and marketable securities were $327 million, and the company guides cash runway through 2028.
ImmuCell reported unaudited results for the quarter ended June 30, 2026, with product sales up 11.5% to $7.2 million and net income of $1.8 million, or $0.20 per diluted share, versus $0.5 million, or $0.06 per basic share, a year earlier. Gross margin fell to 33.9% from 43.7%, and net income includes a one-time $2 million settlement payment from a former contract manufacturer.
Product sales rose 11.5% to approximately $7.2 million in Q2 2026, compared with the quarter ended June 30, 2025.
Gross margin declined to 33.9% of product sales from 43.7%, which the company attributed to lower manufacturing volumes, scrap from a quality issue with a purchased material, and shifted costs from the discontinued Re-Tain program.
Adjusted EBITDA was $2.7 million, compared with $1.4 million a year earlier; cash and cash equivalents rose to $8.9 million at June 30, 2026, from $3.8 million at December 31, 2025.
The company plans a capacity expansion of about $3.5 million (freeze-drying, first phase) and about $4.5 million (colostrum liquid processing, second phase), to be financed with cash on hand and cash from operations.
Capricor reported a second-quarter 2026 net loss of $40.7 million, or $0.70 per share, up from $25.9 million, or $0.57 per share, a year earlier, with no revenue recognized. The company said its FDA Advisory Committee voted 3 in favor and 9 against on cardiomyopathy efficacy for Deramiocel, and it is still working with the FDA on the Biologics License Application.
Q2 2026 net loss of $40.7 million, or $0.70 per share, versus $25.9 million, or $0.57 per share, in Q2 2025
Cash, cash equivalents and marketable securities of $237.9 million at June 30, 2026, down from $318.1 million at December 31, 2025
On July 29, 2026, the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 3 in favor and 9 against; the vote is advisory and non-binding
NS Pharma preliminary injunction motion withdrawn; the company estimates arbitration will begin this fall
Midera Food Processing reported results for the quarter ended July 4, 2026, its first report as an independent public company after its separation from The Middleby Corporation on July 6, 2026. Net sales rose 13.2% and orders rose 16%, and the company raised full-year 2026 guidance, but net earnings fell to $10.8 million from $29.1 million a year earlier. The Board also authorized a share repurchase program of up to $50 million.
Net sales were $245.4 million, up 13.2% from $216.7 million; organic net sales grew 1.2%.
Net earnings were $10.8 million, compared with $29.1 million in the prior year quarter.
Full-year 2026 net sales guidance was raised to $935 million-$965 million from $915 million-$945 million; Estimated Standalone Adjusted EBITDA guidance is $160 million-$176 million.
On August 10, 2026, the Board authorized repurchases of up to $50 million of common stock, expiring August 10, 2029.
TSS, Inc. reported results for the three and six months ended June 30, 2026. Second-quarter revenue fell 20% to $35.1 million, while gross profit and adjusted EBITDA rose, and net income and diluted EPS declined slightly. The company maintained its 2026 adjusted EBITDA outlook at the upper end of its $20 million to $22 million range.
Q2 revenue of $35.1 million, down 20%; systems integration revenue rose 46% to $13.9 million, or 39% of total revenue
Net income of $1.4 million and diluted EPS of $0.05, versus $1.5 million and $0.06 in the year-earlier quarter
Gross profit of $8.0 million, up 11%; adjusted EBITDA of $4.5 million, up 12%
2026 adjusted EBITDA outlook maintained at the upper end of the $20 million to $22 million range
ProMIS Neurosciences reported a net loss of $11.7 million, or $1.28 per share, for the quarter ended June 30, 2026, up from a $10.1 million loss a year earlier. Cash and short-term investments were $53.4 million, which the company says will fund operations through 2027, past the expected first quarter 2027 topline readout from its PRECISE-AD trial. Per-share loss narrowed mainly because of more weighted-average shares after a January 2026 financing.
Q2 2026 net loss was $11.7 million ($1.28 per share), versus $10.1 million ($7.26 per share) in Q2 2025
Cash and short-term investments were $53.4 million at June 30, 2026, up from $6.1 million at December 31, 2025
The increase reflects $70.1 million in net proceeds from a January 2026 private placement, in which certain directors and management participated
Unblinded 12-month PRECISE-AD topline data is expected in the first quarter of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.